Vastcon Inc.

Published purpose

Colorectal cancer (CRC) is one of the most preventable cancers with early detection, but remains the second leading cause of cancer death in Canada and the United States. Given the high impact of CRC, there is an urgent need for a more convenient, more accurate and cost-effective screening test to triage patients for more intensive procedures such as colonoscopy. This would improve patient compliance and clinical outcomes with a significant impact on population health and health care costs. The proposed project aims to clinically validate a simple blood test developed by VastCon for CRC screening. A successful project outcome will allow the company to commercialize their innovation.